Holen Sie sich die Stockscreener-App
118.73
0.64%
0.75
Vorhandelsmarkt:
115.83
-2.90
-2.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave (NASDAQ:GILD) - Seeking Alpha
Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists - Reuters
Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists By Reuters - Investing.com
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Stock Analysis | Gilead Sciences OutlookTechnical Momentum Gathers, But Earnings May Determine Short-Term Fate - AInvest
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
We are positive on Gilead Sciences' base business growth: Meacham - BNN Bloomberg
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
Insider Selling at Gilead Sciences: A Signal of Liquidity or a Cautionary Tale? - AInvest
Mizuho Securities Keeps Buy Rating on Gilead Sciences with $131 Target - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Gilead Sciences CCO Mercier sells $3.3m in shares - Investing.com
Gilead Sciences Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Outlook & Community Verified Swing Trade Signals - beatles.ru
Gilead Sciences CFO sells $296k in shares - Investing.com
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? - Nasdaq
Sure, Biogen (BIIB) Has Been on a Hot Streak Recently But My Bet’s on Gilead Sciences (GILD) - Money Morning
Argus Adjusts Price Target on Gilead Sciences to $130 From $120 - MarketScreener
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use - PMLiVE
Gilead Sciences stock price target raised to $131 from $117 at Mizuho - Investing.com Canada
Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating - MarketScreener
Gilead Sciences' Outperformance Means Overvalued (NASDAQ:GILD) - Seeking Alpha
Short Covering May Lift Gilead Sciences Inc. in Near TermJuly 2025 Patterns & Weekly High Return Forecasts - metal.it
What makes Gilead Sciences Inc. stock attractive todayJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Stock Surges in Trading Volume to 96th Rank Amid 0.55% Drop and Insider Sales - AInvest
Gilead Sciences Appoints New Senior Vice President - The Globe and Mail
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - MSN
Gilead Sciences and the Pricing Strategy of Lenacapavir: Balancing Profit and Public Health in the Fight Against HIV - AInvest
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value - Bloomberg.com
Gilead Sciences' Triple Negative Breast Cancer Study: A Potential Game-Changer for the Oncology Sector - AInvest
Gilead Sciences Sees Decline in Short Interest, Market Sentiment Remains Unclear - AInvest
Gilead Sciences (GILD) Appoints New Senior Vice President and Pr - GuruFocus
Cantor Fitzgerald Keeps Their Buy Rating on Gilead Sciences (GILD) - The Globe and Mail
Drawing Inspiration from Nature: Olivier Nolan-Stevaux’s Work in Oncology Research - Gilead Sciences
Gilead Sciences' Profit Outlook: Beyond the Numbers - AInvest
We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Gilead to buy Nimbus Therapeutics' NASH programme for up to $1.2 billion - FirstWord Pharma
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks - Yahoo Finance
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Gilead, J&J Pare Case on Laurus Copy of HIV Drug to Two Patents - Bloomberg Law News
Gilead stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
Gilead Sciences' Q2 Earnings Call: Growth, Strategic Advances, and Positive Outlook - AInvest
Gilead Sciences' Sacituzumab Govitecan: A Promising New Lung Cancer Treatment - AInvest
Message from the General Manager - Gilead Sciences
Gilead Sciences stock hits 52-week high at 121.67 USD By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at 121.67 USD - Investing.com
Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating - TipRanks
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus - Yahoo Finance
Gilead Sciences Receives Favorable CHMP Opinion for HIV Prevention Drug Lenacapavir - AInvest
Gilead Sciences’ Earnings Call Highlights Growth and Strategic Advances - TipRanks
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir - Insider Monkey
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here - MSN
Gilead Sciences Explores New Dosing for Triple-Negative Breast Cancer Treatment - TipRanks
Gilead Sciences’ Phase 3 Study on Sacituzumab Govitecan: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Gilead Sciences’ Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency - MSN
Deutsche Bank Adjusts Gilead Sciences Price Target to $135 From $120, Maintains Buy Rating - MarketScreener
Factory fallout: Manufacturing plant closures and layoffs from Dow, Gilead Sciences, Whitford, and more - Plant Services
Gilead drops Novo Nordisk-partnered liver disease candidate - medwatch.com
Gilead Sciences soars on strong HIV drug sales - medwatch.com
Gilead Sciences Q2 Earnings Beat Estimates, Shares Surge 8.3% - AInvest
Gilead Sciences (GILD) Is Up 5.5% After Earnings Beat and EU Lenacapavir Milestone – What's Changed - simplywall.st
0.24%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):